{
    "clinical_study": {
        "@rank": "20142", 
        "arm_group": [
            {
                "arm_group_label": "BI 1026706 low dose", 
                "arm_group_type": "Experimental", 
                "description": "BI 1026706 low dose"
            }, 
            {
                "arm_group_label": "BI 1026706 high dose", 
                "arm_group_type": "Experimental", 
                "description": "BI 1026706 high dose"
            }, 
            {
                "arm_group_label": "Placebo reference", 
                "arm_group_type": "Experimental", 
                "description": "Placebo reference"
            }, 
            {
                "arm_group_label": "Celecoxib reference", 
                "arm_group_type": "Experimental", 
                "description": "Celecoxib capsule"
            }
        ], 
        "brief_summary": {
            "textblock": "To investigate the effectiveness of BI 1026706 powder for reconstitution of an oral solution\n      compared to placebo and the relative effectiveness compared to Celecoxib."
        }, 
        "brief_title": "Effectiveness and Safety of Different Doses of BI 1026706 in Patients With Postoperative Dental Pain", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Pain, Postoperative", 
        "condition_browse": {
            "mesh_term": [
                "Pain, Postoperative", 
                "Toothache"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          1. Healthy males according to the investigator's assessment, as based on the following\n             criteria: a complete medical history including a physical examination, vital signs\n             (Blood Pressure,Pulse Rate), 12-lead electrocardiogram, and clinical laboratory tests\n\n          2. Age 18 to 55 years (incl.)\n\n          3. Body Mass Index 18.5 to 29.9 kg/m2 (incl.)\n\n          4. Patients scheduled for removal of one mandibular third molar with partial or complete\n             bony impaction. If medically indicated, the ipsilateral third molar in the upper jaw\n             could also be removed;\n\n          5. Surgery will be conducted under local anaesthesia using 12% lidocaine (with\n             epinephrine). Intravenous sedations and general anaesthetics are not permitted.\n\n          6. Reliable, cooperative, and of adequate intelligence to record the requested\n             information on the analgesic questionnaire form\n\n          7. Examined by the attending oral surgeon or physician and medically cleared to\n             participate in the study\n\n          8. Scheduled to undergo a qualifying surgical procedure\n\n          9. Signed and dated written informed consent prior to admission to the study in\n             accordance with GCP and local legislation\n\n        Exclusion criteria:\n\n          1. Any finding in the medical examination (including Blod Pressure, Pulse Rate or\n             electrocardiogram) deviating from normal and judged clinically relevant by the\n             investigator\n\n          2. Repeated measurement of systolic blood pressure greater than 140 mm Hg or diastolic\n             blood pressure greater than 90 mm Hg\n\n          3. Any laboratory value outside the reference range that the investigator considers to\n             be of clinical relevance\n\n          4. Any evidence of a concomitant disease judged clinically relevant by the investigator\n\n          5. Acute local infection at the time of surgery that could confound the post-surgical\n             evaluation\n\n          6. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,\n             immunological or hormonal disorders\n\n          7. Surgery of the gastrointestinal tract that could interfere with kinetics of the study\n             drug(s)"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 10, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02084511", 
            "org_study_id": "1320.13", 
            "secondary_id": "2013-003580-62"
        }, 
        "intervention": [
            {
                "arm_group_label": "Placebo reference", 
                "description": "Placebo to BI 1026706 solution", 
                "intervention_name": "Placebo to BI 1026706 solution", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 1026706 low dose", 
                "description": "Placebo to BI 1026706 solution", 
                "intervention_name": "Placebo to BI 1026706 solution", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 1026706 low dose", 
                "description": "BI 1026706", 
                "intervention_name": "BI 1026706", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 1026706 high dose", 
                "description": "Placebo to BI 1026706 tablet", 
                "intervention_name": "Placebo to BI 1026706 tablet", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo reference", 
                "description": "Placebo to BI 1026706 tablet", 
                "intervention_name": "Placebo to BI 1026706 tablet", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Celecoxib reference", 
                "description": "Placebo to BI 1026706 solution", 
                "intervention_name": "Placebo to BI 1026706 solution", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 1026706 high dose", 
                "description": "BI 1026706", 
                "intervention_name": "BI 1026706", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 1026706 low dose", 
                "description": "Placebo to BI 1026706 tablet", 
                "intervention_name": "Placebo to BI 1026706 tablet", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Celecoxib reference", 
                "description": "Celecoxib capsule", 
                "intervention_name": "Celecoxib", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Celecoxib"
        }, 
        "lastchanged_date": "May 19, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Verona", 
                    "country": "Italy"
                }, 
                "name": "1320.13.39001 Boehringer Ingelheim Investigational Site"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "4", 
        "official_title": "Effectiveness and Safety of Different Doses of BI 1026706 in Patients With Postoperative Dental Pain (a Single-centre, Partially Double-blinded, Randomised, placebo-and Active Comparator-controlled, Single-dose, Parallel-group Study)", 
        "overall_contact": {
            "email": "clintriage.rdg@boehringer-ingelheim.com", 
            "last_name": "Boehringer Ingelheim Call Center", 
            "phone": "1-800-243-0127"
        }, 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Italy: Ministry of Health"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Time-weighted sum of pain intensity difference (PID) from 0 to 8 hours post drug administration (SPID0-8h)", 
            "safety_issue": "No", 
            "time_frame": "up to 8 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02084511"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Time-weighted total pain relief (PAR) from 0 to 8 hours (TOTPAR0-8h)", 
                "safety_issue": "No", 
                "time_frame": "up to 8 hours"
            }, 
            {
                "measure": "Time-weighted sum of PID from 0 to 2 hours (SPID0-2h)", 
                "safety_issue": "No", 
                "time_frame": "up to 2 hours"
            }, 
            {
                "measure": "Time to meaningful pain relief", 
                "safety_issue": "No", 
                "time_frame": "up to 10 hours"
            }, 
            {
                "measure": "Time to first dose of rescue medication", 
                "safety_issue": "No", 
                "time_frame": "up to 10 hours"
            }
        ], 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}